{"id":"hepatitis-a-virus","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Injection site soreness or erythema"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Myalgia"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_dailymed":{"setId":"cab3c0e1-6358-45e9-ac26-a51b4d4a7af8","title":"VIRI SODE (CYTOMEGALOVIRUS NOSODE, HERPES SIMPLEX I NOSODE, HERPES SIMPLEX II NOSODE, INFLUENZINUM (2024-2025), RUBELLA NOSODE, HEPATITIS A NOSODE, HEPATITIS B NOSODE, HEPATITIS C NOSODE, EPSTEIN BARR VIRUS NOSODE, HERPES ZOSTER NOSODE) SPRAY [NUTRITIONAL SPECIALTIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses. Upon exposure to the antigen, B cells produce specific antibodies (anti-HAV) that neutralize the virus and prevent infection. This provides long-term immunity, typically lasting decades or life.","oneSentence":"Hepatitis A Virus vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:01.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A virus infection in children and adults"}]},"trialDetails":[{"nctId":"NCT07200908","phase":"PHASE3","title":"A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2025-08-27","conditions":"Chronic Hepatitis D Infection","enrollment":172},{"nctId":"NCT05861674","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection","status":"COMPLETED","sponsor":"Huahui Health","startDate":"2023-06-16","conditions":"Chronic Hepatitis Delta Virus Infection","enrollment":101},{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT00023023","phase":"","title":"Study of Transfusion-Transmitted Infections","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-01-17","conditions":"Viral Disease, Blood Donation, Transfusion-Transmitted Infections","enrollment":1771},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":"HEPATITIS B CHRONIC, Hepatitis D, Periodontitis","enrollment":25},{"nctId":"NCT03520660","phase":"PHASE4","title":"People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-10-19","conditions":"Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases","enrollment":121},{"nctId":"NCT07487623","phase":"NA","title":"Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","status":"RECRUITING","sponsor":"University of Guadalajara","startDate":"2025-10-11","conditions":"Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":26},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT01306084","phase":"","title":"Viral Infections in Healthy and Immunocompromised Hosts","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-15","conditions":"Anogenital Herpes, COVID-19, Herpes Labialis","enrollment":1000},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT07096193","phase":"PHASE1, PHASE2","title":"Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-07-31","conditions":"Chronic Hepatitis Delta","enrollment":107},{"nctId":"NCT00004850","phase":"","title":"Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1991-03-15","conditions":"Hepatitis C, Hepatitis B","enrollment":805},{"nctId":"NCT07128550","phase":"PHASE3","title":"A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-07-30","conditions":"Viral Hepatitis","enrollment":150},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT03419481","phase":"PHASE2","title":"Pembrolizumab in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2018-04-30","conditions":"HCC","enrollment":30},{"nctId":"NCT06907290","phase":"PHASE2, PHASE3","title":"A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2025-03-25","conditions":"Chronic Hepatitis D Infection","enrollment":150},{"nctId":"NCT07298330","phase":"PHASE3","title":"A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2026-01-14","conditions":"Chronic Hepatitis D Infection","enrollment":80},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT06953479","phase":"PHASE4","title":"Implementing Low-Barrier HCV Treatment in a Jail Setting","status":"RECRUITING","sponsor":"Lifespan","startDate":"2025-06-11","conditions":"HEPATITIS C (HCV), Incarceration, Injection Drug Use","enrollment":40},{"nctId":"NCT07429864","phase":"","title":"Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-24","conditions":"HBV, HBV Coinfection, HCV","enrollment":20},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":"HIV Infections, Drug Use, Opioid Use","enrollment":447},{"nctId":"NCT07419347","phase":"","title":"Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-02-23","conditions":"Hepatitis C Virus (HCV)","enrollment":2000},{"nctId":"NCT07417553","phase":"PHASE2","title":"A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-03-15","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":150},{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT07412977","phase":"","title":"\"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort\"","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2026-02","conditions":"HIV Infection, HBV Infection, HDV Infection","enrollment":5160},{"nctId":"NCT07406490","phase":"","title":"Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-07-01","conditions":"Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)","enrollment":6466},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05612581","phase":"PHASE1, PHASE2","title":"A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-05-10","conditions":"Hepatitis B, Chronic","enrollment":33},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":"Chronic Hepatitis B Infection","enrollment":200},{"nctId":"NCT06483451","phase":"","title":"Facilitated Telemedicine in the Catholic Health System","status":"NOT_YET_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2026-07","conditions":"HCV","enrollment":200},{"nctId":"NCT07388979","phase":"","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","status":"NOT_YET_RECRUITING","sponsor":"Gardiens de Vies","startDate":"2026-03-01","conditions":"HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus), Hepatitis C Virus (HCV)","enrollment":7500},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05140941","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy","status":"RECRUITING","sponsor":"Catherine Anne Chappell","startDate":"2022-04-04","conditions":"Hepatitis C, Chronic, Pregnancy; Infection","enrollment":100},{"nctId":"NCT06497504","phase":"PHASE2","title":"Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-17","conditions":"Hepatitis B","enrollment":157},{"nctId":"NCT06649266","phase":"PHASE2","title":"Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ribocure Pharmaceuticals AB","startDate":"2024-08-21","conditions":"Chronic Hepatitis D","enrollment":14},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07170748","phase":"","title":"Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2025-07-29","conditions":"Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV","enrollment":2950},{"nctId":"NCT04605679","phase":"NA","title":"Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loma Linda University","startDate":"2020-05-06","conditions":"Kidney Failure","enrollment":31},{"nctId":"NCT07370207","phase":"PHASE2","title":"Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region","status":"NOT_YET_RECRUITING","sponsor":"AusperBio Therapeutics Inc.","startDate":"2026-02-02","conditions":"Hepatitis B, Chronic","enrollment":84},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT03149627","phase":"","title":"Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-07","conditions":"HBV, Alcoholic Hepatitis, Liver Fibroses","enrollment":5003},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT07142811","phase":"PHASE2","title":"A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-08-05","conditions":"Viral Hepatitis","enrollment":100},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT06367465","phase":"","title":"Feasibility and Acceptability of HCV Treatment in Pregnancy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-02-01","conditions":"Hepatitis C, Pregnancy Complications","enrollment":50},{"nctId":"NCT02349126","phase":"PHASE2","title":"Study of ARC-520 in Patient With Chronic Hepatitis B Virus","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT06901362","phase":"","title":"Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"Healthy, Healthy Adult","enrollment":401},{"nctId":"NCT05286879","phase":"NA","title":"Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-03-31","conditions":"Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior","enrollment":600},{"nctId":"NCT06799702","phase":"NA","title":"Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)","status":"NOT_YET_RECRUITING","sponsor":"University of Georgia","startDate":"2026-08-01","conditions":"HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder","enrollment":50},{"nctId":"NCT06494579","phase":"PHASE1, PHASE2","title":"Lamivudine for Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2024-09-26","conditions":"Relapsed/Refractory Solid Tumors","enrollment":12},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":"HIV, HBV (Hepatitis B Virus), HCV","enrollment":50},{"nctId":"NCT05630807","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-07","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":981},{"nctId":"NCT05630820","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-06","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":857},{"nctId":"NCT06766331","phase":"NA","title":"Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2028-04-03","conditions":"Opioid Use Disorder, HIV, Hepatitis C Virus","enrollment":60},{"nctId":"NCT07274345","phase":"","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","status":"NOT_YET_RECRUITING","sponsor":"Amira Mohamed Zidan","startDate":"2025-12-01","conditions":"Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection","enrollment":2000},{"nctId":"NCT04837703","phase":"","title":"MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia","status":"AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Thrombocytopenia","enrollment":""},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT07265544","phase":"","title":"Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-03-01","conditions":"Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD","enrollment":240},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT06659588","phase":"","title":"Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-10","conditions":"Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, Combined Immunodeficiency (CID)","enrollment":120},{"nctId":"NCT06706310","phase":"PHASE2","title":"Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-12-04","conditions":"Chronic Hepatitis B","enrollment":116},{"nctId":"NCT07245953","phase":"PHASE2","title":"A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou HepaThera Biotech Co., Ltd.","startDate":"2025-11-05","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT03826433","phase":"PHASE1","title":"hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis","status":"RECRUITING","sponsor":"Sclnow Biotechnology Co., Ltd.","startDate":"2018-10-01","conditions":"Hepatitis B","enrollment":20},{"nctId":"NCT05248919","phase":"NA","title":"Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2023-06-01","conditions":"Hepatitis C","enrollment":318},{"nctId":"NCT07240350","phase":"","title":"The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-01-01","conditions":"Hepatitis B Virus Infection","enrollment":280},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT06062966","phase":"PHASE1","title":"The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2024-02-05","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT06903338","phase":"PHASE3","title":"A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-03-12","conditions":"Viral Hepatitis","enrollment":124},{"nctId":"NCT03767231","phase":"NA","title":"ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-11","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT05957913","phase":"PHASE2","title":"Effects of Antiviral Therapies on Epstein-Barr Virus Replication","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2023-06-05","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT03365947","phase":"PHASE1, PHASE2","title":"Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2018-03-27","conditions":"Hepatitis B","enrollment":114},{"nctId":"NCT04856085","phase":"PHASE2","title":"Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2021-07-11","conditions":"Hepatitis B, Chronic","enrollment":244},{"nctId":"NCT05904470","phase":"PHASE2","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-05-30","conditions":"Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C","enrollment":275},{"nctId":"NCT04770701","phase":"PHASE4","title":"Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes","status":"COMPLETED","sponsor":"Trieu, Nguyen Thi, M.D.","startDate":"2015-12","conditions":"HIV-1-infection, AIDS","enrollment":60},{"nctId":"NCT05461170","phase":"PHASE2","title":"SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2022-09-17","conditions":"Hepatitis D, Chronic","enrollment":95},{"nctId":"NCT06395129","phase":"","title":"Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries","status":"RECRUITING","sponsor":"Médecins du Monde","startDate":"2024-09-13","conditions":"Drug Use, Hepatitis, Hiv","enrollment":2400},{"nctId":"NCT07137247","phase":"","title":"Immune Dynamics in the Natural History of Chronic HBV Infection","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-02-01","conditions":"HBV (Hepatitis B Virus), HBV Infection, Chronic Hep B","enrollment":5000},{"nctId":"NCT02422875","phase":"","title":"Comparative Autoantibody and Immunologic Cell Marker Study","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2012-08","conditions":"Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases","enrollment":2500},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT06680232","phase":"PHASE1","title":"Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Precision BioSciences, Inc.","startDate":"2024-11-14","conditions":"HEPATITIS B CHRONIC","enrollment":45},{"nctId":"NCT07058974","phase":"PHASE1","title":"A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-08-25","conditions":"Smokers, Former Smokers","enrollment":22},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT07183306","phase":"PHASE1, PHASE2","title":"A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou HepaThera Biotech Co., Ltd.","startDate":"2024-12-30","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03155906","phase":"NA","title":"Integrated Treatment of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2017-05-18","conditions":"Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy","enrollment":298},{"nctId":"NCT05343481","phase":"PHASE2","title":"Efficacy of VTP-300 in Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barinthus Biotherapeutics","startDate":"2022-09-21","conditions":"Chronic Hepatitis B","enrollment":120}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"DRUG INTOLERANCE"},{"count":8,"reaction":"PAIN"},{"count":6,"reaction":"ARTHRALGIA"},{"count":6,"reaction":"COUGH"},{"count":6,"reaction":"FEBRILE NEUTROPENIA"},{"count":6,"reaction":"GASTROINTESTINAL DISORDER"},{"count":5,"reaction":"CELLULITIS"},{"count":5,"reaction":"DRUG HYPERSENSITIVITY"},{"count":5,"reaction":"MUSCLE SPASMS"},{"count":4,"reaction":"ANXIETY"}],"_approvalHistory":[],"publicationCount":6057,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hepatitis A Virus","genericName":"Hepatitis A Virus","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hepatitis A Virus vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A virus infection in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}